---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-24-000049"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:11:31.908863+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Supernus Q2 revenues up 24% to $168.3M; Qelbree sales surge 92%; raises FY2024 guidance

## Summary
- Total Q2 revenues $168.3M (+24% YoY); Qelbree net sales $59.4M (+92% YoY); GOCOVRI $31.7M (+10% YoY)
- Operating income $22.6M; adjusted operating earnings $45.5M, up from $10.0M in Q2 2023
- Raising full-year 2024 guidance for total revenues and operating earnings (GAAP and non-GAAP)
- Resubmitted NDA for apomorphine infusion device (SPN-830) for Parkinson's motor fluctuations
- Phase 2b trial of SPN-820 for TRD expected topline data H1 2025; Phase 2 open-label MDD data by end 2024

## SEC filing metadata
- accession: 0001356576-24-000049
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657624000049/0001356576-24-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657624000049/supn-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-24-000049
- JSON: https://secwatch.observer/filing/0001356576-24-000049.json
- Plain text: https://secwatch.observer/filing/0001356576-24-000049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.